Results 101 to 110 of about 7,353,326 (373)

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. [PDF]

, 2019
Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis.
Carson, Dennis A, Cui, Bing, Ghia, Emanuela M, He, Jinsong, Huang, Jiajia, Jiang, Wenqi, Kipps, Thomas J, Lam, Sharon, Lei, Yang, Messer, Karen, Parker, Barbara A, Schwab, Richard, Widhopf, George F, Wu, Liufeng, Yu, Jian, Zhang, Han, Zhang, Jianchao, Zhang, Suping   +17 more
core   +1 more source

Painting the Capitol Pink: The Breast Cancer Research Stamp and the Dangers of Congressional Cause Marketing [PDF]

, 2020
Breast cancer awareness campaigns—widespread, largescale efforts focusing on general “awareness” of the breast cancer, rather than the dissemination of information on detection and treatment—are common sights in the American public and private spheres ...
Markham Cameron, Julia
core  

Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages [PDF]

, 2018
Background: As crucial regulators of the immune response against pathogens, macrophages have been extensively shown also to be important players in several diseases, including cancer. Specifically, breast cancer macrophages tightly control the angiogenic
Blandino, Giovanni, Donzelli, Sara, Fazi, Francesco, Fontemaggi, Giulia, Gallo, Enzo, Iosue, Ilaria, Masciarelli, Silvia, Melucci, Elisa, Milano, Elisa, Mottolese, Marcella, Pruszko, Magdalena, Sacconi, Andrea, Terrenato, Irene, Zylicz, Alicja, Zylicz, Maciej   +14 more
core   +3 more sources

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

New England Journal of Medicine, 2019
Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer.
G. von Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce‐Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. R. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer   +28 more
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription

Molecular Cancer, 2019
Background The majority of breast cancer patients die of metastasis rather than primary tumors, whereas the molecular mechanisms orchestrating cancer metastasis remains poorly understood.
Bingqiu Xiu, Yayun Chi, Lei Liu, Weiru Chi, Qi Zhang, Jiajian Chen, Rong Guo, Jing Si, Lun Li, Jingyan Xue, Zhi-Ming Shao, Zhao-Hui Wu, Shenglin Huang, Jiong Wu   +13 more
doaj   +1 more source

Communicating biopsy results from breast screening assessment::current practice in English breast screening centres and staff perspectives of telephoning results [PDF]

, 2019
Objective To record how breast screening centres in England deliver all biopsy results (cancer/non-cancer) from the breast assessment visit.Design Online survey of 63 of 79 breast screening centres in England from all regions (East Midlands, East of ...
Casey, Margaret, Ellard, David, Jenkins, Jacquie, Johnson, Rebecca, Kearins, Olive, Sandhu, Harbinder, Taylor Phillips, Sian, Williamson, Sian   +7 more
core   +2 more sources

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Progress of Immunotherapy and Its Application in Triple Negative Breast Cancer

Zhongliu Fangzhi Yanjiu, 2020
In recent years, potential new therapeutic options have been yielded for the immunotherapy of invasive cancers. The most important breakthrough in breast cancer research today is to understand the immune features and profiles of triple negative breast ...
ZHENG Hongmei, FENG Yaojun, XU Juan, CHENG Hongtao, JIN Liting, ZHONG Wei, WU Xinhong   +6 more
doaj   +1 more source